168 related articles for article (PubMed ID: 32976190)
21. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.
Benmassaoud A; Freeman SC; Roccarina D; Plaz Torres MC; Sutton AJ; Cooper NJ; Iogna Prat L; Cowlin M; Milne EJ; Hawkins N; Davidson BR; Pavlov CS; Thorburn D; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013123. PubMed ID: 31978257
[TBL] [Abstract][Full Text] [Related]
22. [Standardization of intensive therapy tactics for acute hepatic insufficiency in patients with liver cirrhosis after portosystem shunting].
Ibadov RA; Babadzhanov AK; Irmatov SK; Gizatulina NR; Ibragimov SK; Ruziboev SA
Khirurgiia (Mosk); 2018; (8):61-67. PubMed ID: 30113595
[TBL] [Abstract][Full Text] [Related]
23. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.
Gu Y; Yang X; Liang H; Li D
BMC Gastroenterol; 2019 Dec; 19(1):231. PubMed ID: 31888534
[TBL] [Abstract][Full Text] [Related]
25. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
[TBL] [Abstract][Full Text] [Related]
26. Should we incorporate long-term use of albumin for patients with decompensated cirrhosis into our daily clinical practice?
Uriz Otano J; López López S; Fernández Rodríguez C
Rev Esp Enferm Dig; 2023 Aug; 115(8):414-417. PubMed ID: 36454075
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of autotaxin for the complications of liver cirrhosis.
Shao X; Uojima H; Setsu T; Okubo T; Atsukawa M; Furuichi Y; Arase Y; Hidaka H; Tanaka Y; Nakazawa T; Kako M; Kagawa T; Iwakiri K; Terai S; Koizumi W
World J Gastroenterol; 2020 Jan; 26(1):97-108. PubMed ID: 31933517
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.
Albillos A; Bañares R; González M; Catalina MV; Molinero LM
J Hepatol; 2005 Dec; 43(6):990-6. PubMed ID: 16139922
[TBL] [Abstract][Full Text] [Related]
29. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
[TBL] [Abstract][Full Text] [Related]
30. Presentation and complications associated with cirrhosis of the liver.
Poordad FF
Curr Med Res Opin; 2015 May; 31(5):925-37. PubMed ID: 25697811
[TBL] [Abstract][Full Text] [Related]
31. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.
Hassanein TI; Tofteng F; Brown RS; McGuire B; Lynch P; Mehta R; Larsen FS; Gornbein J; Stange J; Blei AT
Hepatology; 2007 Dec; 46(6):1853-62. PubMed ID: 17975845
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis.
Wong YJ; Qiu TY; Tam YC; Mohan BP; Gallegos-Orozco JF; Adler DG
Dig Liver Dis; 2020 Oct; 52(10):1137-1142. PubMed ID: 32586766
[TBL] [Abstract][Full Text] [Related]
33. Long-term albumin treatment in patients with cirrhosis and ascites.
Caraceni P; O'Brien A; Gines P
J Hepatol; 2022 Jun; 76(6):1306-1317. PubMed ID: 35589252
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
[TBL] [Abstract][Full Text] [Related]
35. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.
Simón-Talero M; García-Martínez R; Torrens M; Augustin S; Gómez S; Pereira G; Guevara M; Ginés P; Soriano G; Román E; Sánchez-Delgado J; Ferrer R; Nieto JC; Sunyé P; Fuentes I; Esteban R; Córdoba J
J Hepatol; 2013 Dec; 59(6):1184-92. PubMed ID: 23872605
[TBL] [Abstract][Full Text] [Related]
36. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
[TBL] [Abstract][Full Text] [Related]
37. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
38. [The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis].
Zhang JY; Kuai JH; Jia JD; Wang BE; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):263-5. PubMed ID: 19403023
[TBL] [Abstract][Full Text] [Related]
39. Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.
Bai Z; Bernardi M; Yoshida EM; Li H; Guo X; Méndez-Sánchez N; Li Y; Wang R; Deng J; Qi X
Aging (Albany NY); 2019 Oct; 11(19):8502-8525. PubMed ID: 31596729
[TBL] [Abstract][Full Text] [Related]
40. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
